FDA approves Admelog, the first short-acting "follow-on" insulin product to treat diabetes - FDA.gov

Endocrinology Advisor

FDA approves Admelog, the first short-acting "follow-on" insulin product to treat diabetes FDA.gov The U.S. Food and Drug Administration today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and ... New Diabetes Drug Gets FDA OK Under 'Abbreviated' PathwayHealthDay FDA Gives Final OK to First Short-Acting Follow-On Insulin for DiabetesPharmacy Times FDA Approves Sanofi's Admelog® (insulin lispro injection)Nasdaq Endocrinology Advisor -Monthly Prescribing Reference -MD Magazine -Seeking Alpha all 21 news articles »

from Health - Google News http://ift.tt/2BEMU6H